Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor Inmagene...